[Zurück]

A. Bauer, C. Urach, F. Breitenecker:
"Evaluation of Compartment Models for Simulation of Infliximab Depletion";
in: "ERK - International Electrotechnical and Computer Science Conference", Andrej Zemva (Hrg.); herausgegeben von: University of Ljubljana; ERK - International Electrotechnical and Computer Science Conference, Portoroz, 2013, S. 141 - 144.

Infliximab is an antibody that is approved for treatment
of the inflammatory bowel diseases Crohn´s disease and
ulcerative colitis. It is important to predict the course of
the depletion of Infliximab in the body to time the
regular infusions that patients get. The base model is a
two-compartment-model and three parameter
identification approaches are compared: identification
of each infusion period separately, identification of each
patient separately and identification of all measurement
points at once. The best results provides the approach to
identify the parameters for each infusion period
separately. Wanting to improve the quality of the
results, an extended model with continuous parameter
antibodies to Infliximab (ATI) is considered, but the
mean error is higher than for the base model. We
conclude that the presence of antibodies to Infliximab in
the body carries more weight than the actual number of
antibodies. Finally, a model with an additional
parameter, number of previous infusions with Infliximab
(PRIORIFX), is created. This model could not improve
the results of the base model. This indicates that the
number of previous infusions with Infliximab is not
significant for the model.

http://publik.tuwien.ac.at/files/PubDat_224193.pdf